American Association for Cancer Research

Data from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors

Posted on 2024-06-11 - 15:00

Chimeric antigen receptor (CAR) T cells have shown promising results in the treatment of B-cell malignancies. Despite the successes, challenges remain. One of them directly involves the CAR T-cell manufacturing process and especially the ex vivo activation phase. While this is required to allow infection and expansion, ex vivo activation dampens the antitumor potential of CAR T cells. Optimizing the nature of the T cells harboring the CAR is a strategy to address this obstacle and has the potential to improve CAR T-cell therapy, including for solid tumors. Here, we describe a protocol to create CAR T cells without ex vivo preactivation by inhibiting the transcription factor FOXO1 (CAR TAS cells). This approach made T cells directly permissive to lentiviral infection, allowing CAR expression, with enhanced antitumor functions. FOXO1 inhibition in primary T cells (TAS cells) correlated with acquisition of a stem cell memory phenotype, high levels of granzyme B, and increased production of TNFα. TAS cells displayed enhanced proliferative and cytotoxic capacities as well as improved migratory properties. In vivo experiments showed that CAR TAS cells were more efficient at controlling solid tumor growth than classical CAR T cells. The production of CAR TAS from patients’ cells confirmed the feasibility of the protocol in clinic.


3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
AAPG Bulletin
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Select your citation style and then place your mouse over the citation text to select it.


Institut des sciences biologiques (INSB)

Institut National de la Santé et de la Recherche Médicale (Inserm)

Ligue Contre le Cancer (French League Against Cancer)

Inserm Transfert (Inserm Transfert SA)

Bristol-Myers Squibb (BMS)

Assistance Publique - Hôpitaux de Paris (AP-HP)



Usage metrics

Cancer Immunology Research


Maude Marchais
Luca Simula
Mélanie Phayanouvong
Fathia Mami-Chouaib
Georges Bismuth
Justine Decroocq
Didier Bouscary
Jacques Dutrieux
Marianne Mangeney
need help?